Analyzing Pacific Biosciences of California (PACB) & Dynatronics Corporation (DYNT)
Pacific Biosciences of California (NASDAQ: PACB) and Dynatronics Corporation (NASDAQ:DYNT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Risk & Volatility
Pacific Biosciences of California has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Dynatronics Corporation has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500.
This table compares Pacific Biosciences of California and Dynatronics Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-89.67%||-93.31%||-57.10%|
Insider and Institutional Ownership
68.3% of Pacific Biosciences of California shares are held by institutional investors. Comparatively, 17.5% of Dynatronics Corporation shares are held by institutional investors. 17.8% of Pacific Biosciences of California shares are held by insiders. Comparatively, 51.8% of Dynatronics Corporation shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of current recommendations and price targets for Pacific Biosciences of California and Dynatronics Corporation, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||1||0||2.33|
Pacific Biosciences of California currently has a consensus target price of $8.93, suggesting a potential upside of 111.19%. Given Pacific Biosciences of California’s higher probable upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than Dynatronics Corporation.
Valuation and Earnings
This table compares Pacific Biosciences of California and Dynatronics Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$95.83 million||5.10||-$75.40 million||($0.92)||-4.60|
|Dynatronics Corporation||$35.76 million||0.32||-$836,282.00||($1.24)||-1.98|
Dynatronics Corporation has higher revenue, but lower earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Dynatronics Corporation, indicating that it is currently the more affordable of the two stocks.
Pacific Biosciences of California beats Dynatronics Corporation on 7 of the 12 factors compared between the two stocks.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
Dynatronics Corporation Company Profile
Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.
Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.